Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fujikura Exercises Option to License Cellmid’s Diagnostics

Published: Monday, July 22, 2013
Last Updated: Monday, July 22, 2013
Bookmark and Share
License is expected to be signed for multiple cancer diagnostic products.

Cellmid Limited has received confirmation that Fujikura Kasei Co Ltd (Fujikura) will exercise its Option to license the midkine (MK) diagnostic technology by paying the requisite JPY40 million (AUD 440,000) Milestone Fee.

Under the terms of the Option to License agreement, which was signed between the companies in February 2013, Cellmid supplied Fujikura with its proprietary anti-midkine diagnostic antibodies for validation on Fujikura’s latex platform.

Proceeding to a license agreement was conditional on Fujikura reaching accuracy of 500 picogram/ml midkine on its latex diagnostic platform using Cellmid’s antibodies.

Fujikura has since completed this milestone, reached the required accuracy and advised Cellmid of its intention to exercise its Option.

The parties will now proceed to a supply and license agreement for the development and marketing of multiple cancer diagnostic products using Fujikura’s latex assay with Cellmid’s MK antibodies.

The license between the parties is expected to grant exclusive rights to Fujikura to use Cellmid’s proprietary antibodies for latex based tests.

In return, Fujikura will pay royalties on products sold. Product development and marketing costs will be borne by Fujikura.

A latex based test with a 500 picogram/ml accuracy can be used reliably to identify individuals with elevated midkine levels. This in turn is expected to lead to the development of a number of cancer diagnostic products.

Cellmid will support Fujikura’s regulatory and product development programmes with its MK diagnostic expertise.

Cellmid has a highly accurate MK-ELISA already, however a latex based assay will be suitable for commercial products, as it is widely used and accepted in pathology laboratories. It is also preferred as it can easily be automated, reducing processing costs.

Fujikura Kasei is one of the largest suppliers of latex particles for the medical diagnostics industry in Japan. While traditionally servicing other industries with polymers and resins, Fujikura has been actively expanding into medical diagnostics.

“We are pleased with the progress of our project with Cellmid and looking forward to developing and marketing a number of cancer diagnostic products using midkine as a key marker on our platform” said Fujikura’s Head of Medical Project Division, Dr Hideyuki Kuroda.

Cellmid CEO Maria Halasz said she was impressed by Fujikura’s technical skills in developing a latex based midkine test.

“With Fujikura’s strong focus on building market share in proprietary cancer tests our MK diagnostic technology is in good hands” she said.

Midkine has been extensively validated as an early marker for a range of cancers and has been shown to be useful in prognosis and disease management.

A license agreement involving MK for the early diagnosis, prognosis and disease monitoring of lung cancer was signed in 2009 with Celera-Quest, and for bladder cancer in 2010 with Pacific Edge Biotechnology.

A license with Fujikura Kasei involving multiple cancer indications further validates the Company’s technology, including the quality of its reagents.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Zika Reference Strain Sequenced
An international research team has sequenced a strain of Zika for use as a WHO reference strain.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!